A Phase 2 interventional study of alemtuzumab and methylprednisolone in Breast Cancer, Chronic Myeloproliferative Disorders and Gestational Trophoblastic Tumor, sponsored by Fred Hutchinson Cancer Center. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2010-05-14.
Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Supportive care
RATIONALE: Alemtuzumab and glucocorticoids, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
PURPOSE: This phase II trial is studying how well giving alemtuzumab together with glucocorticoids works in treating newly diagnosed acute graft-versus-host disease in patients who have undergone donor stem cell transplant.
OBJECTIVES:
OUTLINE: This is an open-label, nonrandomized study.
Within 72 hours of beginning glucocorticoid therapy, patients receive alemtuzumab IV over at least 2 hours on days 1 and 2. If graft-versus-host disease (GVHD) responds well during days 1-14 but returns between days 28 and 56, patients are eligible to receive 2 additional doses of alemtuzumab.
Patients receive glucocorticoid therapy comprising methylprednisolone IV or oral prednisone daily until objective evidence of improvement in manifestations of GVHD. Patients with resolved or significantly improved GVHD receive treatment until day 10 followed by an accelerated taper until day 72 if no flare up of GVHD occurs during the glucocorticoid taper. Patients with recurrent or progressive GVHD during the accelerated taper are treated for 5-7 days before resuming a less rapid taper. Patients with no improvement may receive secondary therapy with alternative immunosuppressive medications at the discretion of the managing physician. Treatment continues in the absence of progressive GVHD of at least 3 days duration during days 2-10; persisting GVHD without improvement between days 10-14; recurrent or progressive GVHD after day 10 that does not respond within 3 days to topical immunosuppressive therapy; and/or an increase in the systemic glucocorticoid dose by two taper steps; or unacceptable toxicity.
Patients undergo blood collection at baseline and then periodically during study treatment for pharmacokinetics and quantification of viral loads for human herpes virus 6, adenovirus, Epstein-Barr virus, and cytomegalovirus. Samples are also examined by flow cytometry for B- and T-cell quantification at baseline, periodically during study treatment, and at 1 year after transplantation.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 53 patients will be accrued for this study.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's planned enrollment of 53 is above the median of 40 across 4,508 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →Fred Hutchinson Cancer Center is the lead sponsor of 537 studies on the registry; 79 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 45 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
DISEASE CHARACTERISTICS:
Newly diagnosed acute graft-versus-host disease (GVHD)
Requires glucocorticoids for treatment of GVHD, as indicated by 1 of the following:
Initial treatment with prednisone or methylprednisolone at 2 mg/kg is indicated (in the judgement of the attending physician) by any of the following:
Has undergone allogeneic HSCT with myeloablative conditioning
No primary treatment of acute GVHD with methylprednisolone at any of the following doses:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Proportion of patients with methylprednisolone (MP)-equivalent glucocorticoid doses ≤ 0.75 mg/kg on day 28 after starting therapy for graft-versus-host disease (GVHD)
Total cumulative dose of MP-equivalent treatment during the first 8 weeks after study entry
Proportion of patients with complete response, measured weekly through day 56
Incidence of secondary systemic therapy for acute GVHD
Cumulative acute GVHD activity index score at day 56
Incidence of chronic GVHD at 1 year
Nonrelapsing mortality at 1 year
Survival at 1 year
Cumulative incidence of opportunistic infections at 1 year
Cumulative incidence of recurrent or progressive malignancy at 1 year
Peripheral blood CD4, CD8, CD19, and CD16/56 counts at baseline and then periodically for 1 year
This study is completed, as verified in May 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fred Hutchinson Cancer Center